MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

ACADIA Pharmaceuticals Inc

Abierto

SectorSalud

14.63 0.21

Resumen

Variación precio

24h

Actual

Mínimo

14.4

Máximo

14.83

Métricas clave

By Trading Economics

Ingresos

111M

144M

Ventas

9.2M

260M

P/B

Media del Sector

10.574

57.333

BPA

0.86

Margen de beneficio

55.37

Empleados

653

EBITDA

-19M

12M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+74.42% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-706M

2.4B

Apertura anterior

14.42

Cierre anterior

14.63

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

ACADIA Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

24 abr 2025, 23:54 UTC

Acciones populares

Stocks to Watch: Alphabet, Intel, AppFolio

24 abr 2025, 23:51 UTC

Charlas de Mercado

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 abr 2025, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 abr 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 abr 2025, 23:37 UTC

Principales Noticias

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 abr 2025, 23:36 UTC

Principales Noticias

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 abr 2025, 23:13 UTC

Principales Noticias
Ganancias

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 abr 2025, 23:09 UTC

Principales Noticias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 abr 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 abr 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 abr 2025, 22:51 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 abr 2025, 22:48 UTC

Principales Noticias

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 abr 2025, 22:47 UTC

Charlas de Mercado

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 abr 2025, 22:38 UTC

Charlas de Mercado
Ganancias

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 abr 2025, 22:24 UTC

Ganancias

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 abr 2025, 22:24 UTC

Ganancias

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 abr 2025, 22:24 UTC

Charlas de Mercado
Ganancias

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 abr 2025, 22:23 UTC

Ganancias

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 abr 2025, 22:11 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

24 abr 2025, 22:11 UTC

Charlas de Mercado
Ganancias

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 abr 2025, 22:09 UTC

Principales Noticias
Ganancias

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 abr 2025, 22:00 UTC

Charlas de Mercado
Ganancias

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 abr 2025, 21:39 UTC

Principales Noticias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 abr 2025, 21:24 UTC

Principales Noticias
Ganancias

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 abr 2025, 21:24 UTC

Principales Noticias
Ganancias

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 abr 2025, 21:23 UTC

Principales Noticias
Ganancias

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 abr 2025, 21:04 UTC

Ganancias

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 abr 2025, 21:03 UTC

Ganancias

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 abr 2025, 21:03 UTC

Ganancias

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 abr 2025, 21:02 UTC

Ganancias

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparación entre iguales

Cambio de precio

ACADIA Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

74.42% repunte

Estimación a 12 meses

Media 25.5 USD  74.42%

Máximo 37 USD

Mínimo 18 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ACADIA Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

16 ratings

10

Comprar

6

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.76 / 14.995Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.